Viridian Therapeutics enters $300M ATM equity offering with Jefferies; terminates prior $175M ATM

Viridian Therapeutics, Inc.\DE

New Open Market Sale Agreement with Jefferies LLC allows sale of up to $300M in common stock.
Proceeds to fund clinical development of veligrotug and other candidates, plus commercialization preparation.
Prior $175M ATM agreement terminated; $115.2M of shares sold under it.
Jefferies will receive up to 3% commission on gross proceeds; no obligation to sell shares.
Company may suspend or terminate sales at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.